Summaries & Associations of Study Results
TR-468 Oxazepam
Target Organs and Levels of Evidence
NTP Technical Report Number 468
Produced from Chemtrack Database 09/19/01
CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
---|---|---|---|---|
OXAZEPAM 604-75-1 |
12/11/96 | TRANQUILIZER | Dosed-Feed 0, 625, 1250, 2500, 5000, OR 10000 PPM; 50/SEX/GROUP | Battelle Columbus Laboratory |
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
MR: EQUIVOCAL EVIDENCE | KIDNEY TUBULAR CELL: (SINGLE SECTIONS) ADENOMA 1/50 0/50 3/50 1/50 (SINGLE AND STEP SECTIONS) 2/50 1/50 7/50 6/50; (STOP STUDY) SINGLE SECTIONS 0/50, SINGLE AND STEP SECTIONS 6/45 | |||
NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | |||
FORESTOMACH: CHRONIC INFLAMMATION; ULCER; EPITHELIAL HYPERPLASIA | ||||
GLANDULAR STOMACH: MINERALIZATION | ||||
INTESTINES: DUODENUM, EROSION | ||||
LIVER: HEPATOCYTE CENTRILOBULAR HYPERTROPHY | ||||
FR: NO EVIDENCE | ||||
NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | |||
FORESTOMACH: CHRONIC INFLAMMATION; ULCER; EPITHELIAL HYPERPLASIA | ||||
GLANDULAR STOMACH: EROSION | ||||
LIVER: HEPATOCYTE CENTRILOBULAR HYPERTROPHY |
Web page last updated on February 10, 2006